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IMPORTANCE Multiple therapies are currently available for patients with neuroendocrine
tumors (NETs), yet many therapies have not been compared head-to-head within
randomized clinical trials (RCTs).
OBJECTIVE To assess the relative safety and efficacy of therapies for NETs.
DATA SOURCES PubMed, Embase, the Cochrane Central Register of Controlled Trials, trial
registries, meeting abstracts, and reference lists from January 1, 1947, to March 2, 2018, were
searched. Key search terms included neuroendocrine tumors, gastrointestinal neoplasms,
therapy, and randomized controlled trial.
STUDY SELECTION Randomized clinical trials comparing 2 or more therapies in patients with
NETs (primarily gastrointestinal and pancreatic) were evaluated. Thirty RCTs met the
selection criteria.
DATA EXTRACTION AND SYNTHESIS Pairs of independent reviewers screened studies,
extracted data, and assessed the risk of bias. A network meta-analysis with a frequentist
approach was used to compare the efficacy of therapies; the Preferred Reporting Items
for Systematic Reviews and Meta-analyses guideline was used.
MAIN OUTCOMES AND MEASURES Disease control, progression-free survival, overall survival,
adverse events, and quality of life.
RESULTS The systematic review identified 30 relevant RCTs comprising 3895 patients
(48.4% women) assigned to 22 different therapies for NETs. These therapies showed a broad
range of risk for serious and nonserious adverse events. The network meta-analyses included
16 RCTs with predominantly a low risk of bias; nevertheless, precision-of-treatment estimates
and estimated heterogeneity were limited. The network meta-analysis found 7 therapies for
pancreatic NETs: everolimus (hazard ratio [HR], 0.35 [95% CI, 0.28-0.45]), everolimus plus
somatostatin analogue (HR, 0.35 [95% CI, 0.25-0.51]), everolimus plus bevacizumab plus
somatostatin analogue (HR, 0.44 [95% CI, 0.26-0.75]), interferon (HR, 0.37 [95% CI,
0.16-0.83]), interferon plus somatostatin analogue (HR, 0.31 [95% CI, 0.13-0.71]),
somatostatin analogue (HR, 0.46 [95% CI, 0.33-0.66]), and sunitinib (HR, 0.42 [95% CI,
0.26-0.67]), and 5 therapies for gastrointestinal NETs: bevacizumab plus somatostatin
analogue (HR, 0.22 [95% CI, 0.05-0.99]), everolimus plus somatostatin analogue (HR, 0.31
[95% CI, 0.11-0.90]), interferon plus somatostatin analogue (HR, 0.27 [95% CI, 0.07-0.96]),
Lu 177–dotatate plus somatostatin analogue (HR, 0.08 [95% CI, 0.03-0.26], and
somatostatin analogues (HR, 0.40 [95% CI, 0.21-0.78]) with higher efficacy than placebo and
suggests an overall superiority of combination therapies.
CONCLUSIONS AND RELEVANCE The findings from this study suggest that a range of efficient
therapies with different safety profiles is available for patients with NETs.
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T he treatment of neuroendocrine tumors (NETs) is an in-terdisciplinary and dynamic field with many recent in-novations from industry and academia. These success-
ful treatments include the mechanistic target of rapamycin
inhibitor everolimus,1 the multitargeted receptor tyrosine ki-
nase inhibitor sunitinib,2 the vascular endothelial growth fac-
tor antibody bevacizumab,3 the radiolabeled somatostatin ana-
logue lutetium-177 (177Lu)-dotatate,4 and new combinations
of previously established therapies.5
Several of these new therapies have demonstrated effi-
cacy in randomized clinical trials (RCTs); however, translation
of these results into widespread improved patient care faces sev-
eral challenges. First, a therapeutic reference standard for treat-
ment of NETs is lacking, and several therapies were compared
only with placebo. Second, direct comparison of the most per-
tinent therapies is incomplete, complicating clinical decision
making in selecting one therapy over another. Third, even
though innovative and effective combinations of existing thera-
pies have been developed in academic settings, they are often
associated with a lack of representation in clinical guidelines.6
We believe this systematic review and network meta-analysis
of RCTs will satisfy the need for compiling and evaluating the
available evidence on the safety and efficacy of NET therapies.
Methods
The study was designed and conducted according to the Coch-
rane Handbook for Systematic Reviews of Interventions.7 The re-
port was prepared according to the Preferred Reporting Items for
Systematic Reviews and Meta-analyses statement for systematic
reviews8,9 and its extension for network meta-analyses.10
Literature Search
We aimed to identify all RCTs comparing therapeutic inter-
ventions in NETs. In collaboration with Cochrane Switzer-
land, we developed a sensitive search algorithm using MeSH
terms and text words in combination with an RCT filter (eTable 1
in the Supplement). Using this algorithm, we searched PubMed,
Embase, and the Cochrane Central Register of Controlled Trials
for studies reported from January 1, 1947, until March 2, 2018.
We did not impose language or date restrictions or any exclu-
sion criteria. In addition, we manually searched the trial reg-
istries ClinicalTrials.gov and the World Health Organization In-
ternational Clinical Trials Registry Platform Search Portal
(http://apps.who.int/trialsearch) for unpublished eligible
trials. We then screened the abstracts from relevant meetings
in 2017 and 2018, such as the annual conference of the
American Society of Clinical Oncology, the North American
Neuroendocrine Tumor Society (NANETS), and the European
Neuroendocrine Tumor Society (ENETS), and searched the
reference lists of included RCTs and relevant reviews. Key
search terms included neuroendocrine tumors, gastrointestinal
neoplasms, therapy, and randomized controlled trial.
Study Selection
For the qualitative analysis, we included RCTs comparing a
therapeutic intervention with placebo or with an active thera-
peutic intervention in patients with NETs. For the quantita-
tive analysis, we included all RCTs reporting disease control
after 12 months and/or progression-free survival. Eight inves-
tigators (R.M.K., M.S., A.K., C.A.S., E.R.C., P.R., M.B., M.A.W.)
working in duplicate independently screened titles and ab-
stracts for potentially relevant studies. Five investigators
(R.M.K., C.A.S., E.R.C., P.R., M.B.) working in duplicate and
then independently screened the full-text report of all poten-
tially relevant studies. Discordances were discussed with a third
reviewer (M.A.W.) and resolved by consensus.
Outcomes and Data Extraction
Efficacy outcomes were disease control, progression-free sur-
vival, overall survival, and quality of life. Safety outcomes were
nonserious and serious adverse events. If values for disease
control rate were not available, we used the sum of the rates
of complete response, partial response, and stable disease, or
100% minus the rate of disease progression. We extracted ab-
solute values, hazard ratios (HRs), and 95% CIs for progression-
free survival and overall survival. We also extracted data on
sex, age, tumor type, tumor grading, metastases, functional
tumors, follow-up duration, follow-up completeness, sample
size calculation, study size, and industry sponsorship. Three
investigators (R.M.K., M.S., A.K.) working in duplicate inde-
pendently extracted all data. Discordances were discussed with
a third reviewer (M.A.W.) and resolved by consensus. We con-
tacted the corresponding authors of included RCTs to re-
quest additional information if needed, and we assessed the
inclusion of RCTs in the recent pertinent guidelines.
Risk of Bias and Quality of Evidence
We assessed the risk of bias for all included RCTs with the Coch-
rane Risk of Bias Tool7 and evaluated the quality of evidence
using the Grading of Recommendations Assessment, Devel-
opment, and Evaluation (GRADE).11,12 The details for these as-
sessments are presented in the eMethods in the Supplement.
Statistical Analysis
We performed a network meta-analysis with a frequentist ap-
proach using the netmeta package13,14 in R, version 3.5 .15 We
analyzed the end points disease control after 12 months and
progression-free survival each for pancreatic NET (pNET) and
Key Points
Question What is the available evidence on therapies for
neuroendocrine tumors?
Findings This systematic review and network meta-analysis
identified 30 relevant randomized clinical trials comprising 3895
patients with neuroendocrine tumors assigned to 22 different
therapies. A network meta-analysis identified 7 therapies for
pancreatic neuroendocrine tumors and 5 therapies for
gastrointestinal neuroendocrine tumors with a broad range of
different toxic effects and higher efficacy than placebo.
Meaning There appears to be a range of efficient therapies with
different safety profiles available for patients with neuroendocrine
tumors.
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gastrointestinal NET (GI-NET). We applied a continuity cor-
rection for studies with a 0 cell count by adding 0.5 to all cell
frequencies. We ranked therapies based on P scores, measur-
ing the extent of certainty that a treatment is better than an-
other, averaged over all competing therapies.16
If applicable, we assessed heterogeneity by the between-
study-variance τ,2 Cochran Q (weighted sum of squared dif-
ferences between individual study effects and the pooled ef-
fect across studies), and I2 (percentage of variation across
studies due to heterogeneity rather than chance). If quantifi-
cation of heterogeneity was not possible, we fitted fixed-
effect models; otherwise, we used random-effects models. We
assumed consistency for all networks but could not assess it
completely owing to the low number of studies.
We quantified inconsistency by a net split analysis in which
direct and indirect estimates were compared and a calcula-
tion of the between-design part of Cochran Q analysis. We sum-
marized all results using forest plots with combined effect es-
timates (ie, odds ratios and HRs, 95% CIs, and size of boxes
proportional to the inverse of the SEs).
Two RCTs17,18 in the network meta-analysis did not re-
port HRs. Although the number of events did not match the
Kaplan-Meier curves in 1 RCT,17 all reported events could be
identified in the Kaplan-Meier curves of the other RCT.18 We
contacted the author teams of these trials but did not obtain
further data. Thus, we estimated HRs for both RCTs from re-
constructed curves by using a Cox proportional hazards re-
gression model and by disregarding the given number of events
not matching the Kaplan-Meier curves.17 Two-tailed P values
<.05 were considered to indicate statistical significance.
Results
Study Selection
We screened 3671 titles and abstracts and 150 full-text ar-
ticles and found 38 relevant publications reporting 30 pri-
mary RCTs and 8 subgroup analyses (eFigure 1 in the Supple-
ment). One of these primary RCTs19 and 5 of these subgroup
analyses,20-25 with 1 reported in 2 studies,23,24 were available
solely as conference abstracts. A total of 16 RCTs reported dis-
ease control and/or progression-free survival and were in-
cluded in the network meta-analyses. Many of the RCTs were
reported in more than 1 publication.
Study Characteristics
The 30 relevant RCTs were conducted in 41 countries on 5 con-
tinents and were published between 1980 and 2018. Eleven
RCTs included mainly GI-NETs, 9 included mainly pNETs,
8 included GI-NETs and pNETs, and 2 did not specify the type.
Overall, 3895 patients were recruited; 22 different therapies
were evaluated, including biotherapies, chemotherapies, tar-
geted drugs, locoregional therapies, surgical treatment, and
targeted radiopeptide therapy. Most of the 16 RCTs in the net-
work meta-analysis were industry sponsored, and most of the
2944 included patients with metastatic NETs. Further char-
acteristics of included RCTs and patients are provided in
eTables 2 and 3 in the Supplement. The characteristics of RCTs
and subgroup-analyses not in the network meta-analysis are
reported in eTable 4 in the Supplement, and the characteris-
tics of their respective patients are reported in eTable 5 in the
Supplement.
Risk of Bias
Among 30 RCTs and 8 subgroup analyses, 20 had low risk for
bias in random sequence generation (selection bias, 53%), 20
had low risk for bias in allocation concealment (selection bias,
53%), 21 had low risk for bias in blinding participants and per-
sonnel (performance bias, 55%), 19 had low risk for bias in
blinding the outcome assessment (detection bias, 50%), 32 had
low risk for bias of incomplete outcome data (attrition bias,
84%), and 32 had low risk for bias of selective reporting (re-
porting bias, 84%) (eTable 6 in the Supplement). Overall, 26
publications (68%) were free of high risk for bias in all of the
above-mentioned domains.
Treatment Efficacy in pNETs
Eight RCTs compared disease control rates for 8 different thera-
pies in pNETs (Figure 1A).2,5,17,26-33 The network meta-
analysis found that single therapy with everolimus and com-
bination therapies were highly effective. Specifically,
everolimus (P score, 0.82), everolimus plus a somatostatin ana-
logue (P score, 0.73), and interferon plus a somatostatin ana-
logue (P score, 0.71) achieved the highest disease control rates,
followed by single treatment with interferon (P score, 0.62),
somatostatin analogues (P score, 0.54), sunitinib (P score, 0.39),
placebo (P score, 0.13), and dactolisib (P score, 0.06). All thera-
pies except interferon, sunitinib, and dactolisib showed sig-
nificantly higher disease control rates than placebo (Figure 1C;
eFigure 2 in the Supplement).
In addit ion, 8 RCTs (one 3-arm trial ) assessed
progression-free survival for 9 different therapies in pNETs
(Figure 1B).2,5,17,26-29,32-35 The network meta-analysis found
that combination therapies were highly effective, with HRs
between 0.31 and 0.35 vs placebo. The lowest hazard for pro-
gression was found after treatment with interferon plus a
somatostatin analogue (P score, 0.77), followed by everoli-
mus plus a somatostatin analogue (P score, 0.72), everolimus
(P score, 0.72), interferon (P score, 0.62), sunitinib (P score,
0.51), everolimus plus bevacizumab plus a somatostatin ana-
logue (P score, 0.44), somatostatin analogues (P score, 0.37),
dactolisib (P score, 0.33), and placebo (P score, 0.01). All
therapies but dactolisib significantly reduced the hazard for
progression compared with placebo (Figure 1D; eFigure 3 in
the Supplement). The quality of evidence in pNETs was gen-
erally the highest for comparisons including everolimus. The
detailed results of the quality assessment are displayed in
eTables 7 and 8 in the Supplement.
Treatment Efficacy in GI-NETs
Ten RCTs assessed disease control rates for 9 different thera-
pies in GI-NETs (Figure 2A).1,5,17,18,26,30,31,36-40 Again, the net-
work meta-analysis found that combination therapies were
highly effective. Bevacizumab plus a somatostatin analogue
resulted in the highest disease control rate (P score, 0.93), fol-
lowed by 177Lu-dotatate plus a somatostatin analogue (P score,
Research Original Investigation Therapeutic Options for Neuroendocrine Tumors
482 JAMA Oncology April 2019 Volume 5, Number 4 (Reprinted) jamaoncology.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Universität Bern User  on 12/19/2019
0.92), interferon plus a somatostatin analogue (P score, 0.66),
everolimus plus a somatostatin analogue (P score, 0.53), in-
terferon (P score, 0.52), somatostatin analogues (P score, 0.40),
everolimus (P score, 0.39), placebo (P score, 0.12), and strep-
tozocin plus fluorouracil (P score, 0.04). All therapies but in-
terferon, everolimus, and streptozocin plus fluorouracil
showed significantly higher disease control rates than pla-
cebo (Figure 2C; eFigure 4 in the Supplement).
Eight RCTs assessed progression-free survival for 8 dif-
ferent therapies in GI-NETs (Figure 2B) and, again, the
network meta-analysis found that combination therapies
were highly effective, with HRs between 0.08 and 0.31 vs
placebo.1,3,5,17,18,26,31,36,37,40 The lowest hazard for progres-
sion was found after treatment with 177Lu-dotatate plus a so-
matostatin analogue (P score, 0.97), followed by bevaci-
zumab plus a somatostatin analogue (P score, 0.68), interferon
plus a somatostatin analogue (P score, 0.59), everolimus plus
a somatostatin analogue (P score, 0.53), interferon (P score,
0.50), somatostatin analogues (P score, 0.38), everolimus
(P score, 0.33), and placebo (P score, 0.02). All therapies but
interferon and everolimus significantly reduced the hazard for
progression compared with placebo (Figure 2D; eFigure 5 in
the Supplement). The quality of evidence in GI-NETs was gen-
erally the highest for comparisons including somatostatin
analogues. The detailed results of the quality assessment are
displayed in eTables 9 and 10 in the Supplement.
Disease Control, Progression-Free Survival,
and Overall Survival
Twelve RCTs reported data on disease control and progression-
free survival,1,2,5,17,18,26-29,36,37,41 and both outcomes were gen-
erally positively associated (eFigure 6 in the Supplement).
Figure 1. Treatment Efficacy in Pancreatic Neuroendocrine Tumors (pNETs)
Favors Decreased
Disease Control
Favors Increased
Disease Control
OR (95% CI)
No./Total No.
of Patients
GRADE
Quality of
EvidenceSource
OR
(95% CI)
4Everolimus 3.29 (2.21-4.90) 
4Everolimus + SSA 2.89 (1.61-5.19) 
1Interferon + SSA 2.88 (1.16-7.13) 
1Interferon 2.58 (0.75-8.81) 
2SSA 2.36 (1.43-3.88) 
Subtotal τ2 = not estimable; I2 = not estimable; Cochran Q = 1.112; P =.58
Disease control in pNETC
Network disease control in pNETA Network PFS in pNETB
2Sunitinib 1.72 (0.91-3.27) 
1Dactolisib 0.56 (0.13-2.37) 
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Progression
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100.1
HR (95% CI)
Total No.
of Patients
GRADE
Quality of
EvidenceSource
HR
(95% CI)
370 4Everolimus + SSA 0.35 (0.25-0.51)
319 4Everolimus 0.35 (0.28-0.45)
23 2Interferon 0.37 (0.16-0.83)
86 3Sunitinib 0.42 (0.26-0.67)
75 1Everolimus + bevacizumab + SSA 0.44 (0.26-0.75)
Subtotal τ2 = not estimable; I2 = not estimable; Cochran Q = 1.011; P =.91
PFS in pNETD
336 3SSA 0.46 (0.33-0.66)
31 1Dactolisib 0.54 (0.24-1.19)
391vs Placebo
21 2Interferon + SSA 0.31 (0.13-0.71)
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Network plots for disease control (A)
and progression-free survival (PFS)
(B) in pNETs. The thickness of the
edges is proportional to the inverse
SEs of the pairwise comparisons, and
the numbers indicate the number of
studies. One 3-arm study is marked
by shading. C and D, Forest plots for
disease control and PFS, respectively,
in pNETs. The forest plots include
only comparisons vs placebo. An
odds ratio (OR) larger than 1 indicates
increased disease control of the
active treatment and a hazard ratio
(HR) smaller than 1 indicates a
reduced risk for progression for the
active treatment. An HR smaller than
1 indicates a reduced risk for
progression. All therapies are listed in
order of their P scores, with the most
effective therapy at the top.
Heterogeneity was assessed by the
between-study variance τ2 value,
Cochran Q with a P value, and I2.
Total No. refers to the total number
of patients, and No. to the number
of patients with disease control.
The Grading of Recommendations
Assessment, Development and
Evaluation (GRADE) approach was
used to rate the quality of evidence of
estimates from pairwise and network
meta-analysis, where 1 is very low;
2, low; 3, moderate; and 4, high.
SSA indicates somatostatin analogue.
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Moreover, 11 RCTs reported data on overall survival (eTable 11
in the Supplement),2,19,29,30,32-35,42-44 and 8 RCTs reported both
progression-free survival and overall survival.1-3,29,34,36,37,42 In
each of these RCTs, superiority of a therapy regarding progres-
sion-free survival was associated with superiority regarding
overall survival.
Quality of Life and Safety
Ten RCTs reported effects on quality of life,1,2,26,30,31,
33,35,36,40,42,44-48 and 7 of these quantified changes for 7 dif-
ferent therapies with the Quality of Life Questionnaire C30
of the European Organization for Research and Treatment
of Cancer.2,26,30,31,33,35,36,42,44-46 Of these, telotristat
etiprate had the greatest effect on improving quality
of life, followed by somatostatin analogues (eTable 12 in
the Supplement). Furthermore, 12 RCTs and 7 subgroup
analyses1,26-29,31,32,37,39-42,45,46,49,50 reported frequencies of ad-
verse events for 12 different therapies, of which dactolisib
showed the highest and interferon plus a somatostatin ana-
logue showed the lowest rates of serious adverse events (83.9%
vs 3.0%) (Table). Adverse events were classified according to
the National Cancer Institute Common Terminology Criteria
for Adverse Events (grade 1, mild; grade 2, moderate; grade 3,
severe or medically significant; grade 4, life-threatening).51
Representation in International Guidelines
Only 14 of the existing 30 RCTs and 8 subgroup analyses (37%)
on NET treatment were included in both the latest NANETS and
ENETS consensus guidelines (eTables 2 and 4 in the Supple-
ment); thus, 63% were not included in both guidelines.
Figure 2. Treatment Efficacy in Gastrointestinal Neuroendocrine Tumors (GI-NETs)
Favors
Decreased
Disease Control
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Disease Control
OR (95% CI)
No./Total No.
of Patients
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Quality of
EvidenceSource
OR
(95% CI)
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1Interferon 4.03 (0.86-18.80) 
Subtotal τ2 = 0.17; I2 = 43.4%; Cochran Q = 5.303; P =.15
Disease Control in GI-NETC
Network disease control in GI-NETA Network PFS in GI-NETB
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245 1Interferon + SSA 0.27 (0.07-0.96)
216 1Everolimus + SSA 0.31 (0.11-0.90) 
23 1Interferon 0.32 (0.09-1.14) 
491 2SSA 0.40 (0.21-0.78) 
Subtotal τ2 = 0.16; I2 = 58.8%; Cochran Q = 4.862; P =.09
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Network plots for disease control (A)
and progression-free survival (PFS)
(B) in GI-NETs. The thickness of the
edges is proportional to the inverse
SEs of the pairwise comparisons, and
the numbers indicate the number of
studies. One 3-arm study is marked
by shading. C and D, Forest plots for
disease control and PFS, respectively,
in GI-NET. The forest plots include
only comparisons vs placebo. An
odds ratio (OR) larger than 1 indicates
increased disease control of the
active treatment and a hazard ratio
(HR) smaller than 1 indicates a
reduced risk for progression for the
active treatment. An HR smaller than
1 indicates a reduced risk for
progression. All therapies are listed in
order of their P scores, with the most
effective therapy at the top.
Heterogeneity was assessed by the
between-study variance τ2 value,
Cochran Q with a P value, and I2. Total
No. refers to the total number of
patients, and No. to the number of
patients with disease control. The
Grading of Recommendations
Assessment, Development and
Evaluation (GRADE) approach was
used to rate the quality of evidence of
estimates from pairwise and network
meta-analysis, where 1 is very low;
2, low; 3, moderate; and 4, high.
177Lu-dotatate indicates radiolabeled
lutetium Lu 177-dotatate;
SSA, somatostatin analogue.
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Specifically, 12 of 27 publications (44%) with industry
sponsoring1-3,5,17,26,29-33,35-37,40,46,49 and 2 of 11 publications
(18%) without industry sponsoring43,48 were included in both
guidelines (eTables 2 and 4 in the Supplement).
Discussion
This systematic review identified 30 RCTs that randomized
3895 patients to 22 different therapies. To our knowledge, this
represents the most comprehensive overview of the avail-
able safety and efficacy data for NET therapies, and its main
findings can be summarized as follows.
First, the results suggest a superiority of combination
therapies, especially of those including somatostatin ana-
logues. In pNETs, somatostatin analogues plus interferon,
everolimus, or everolimus plus bevacizumab were highly
efficacious. The certainty of evidence for these therapies
was variable and was the highest for somatostatin analogues
plus everolimus. In GI-NETs, somatostatin analogues plus
177Lu-dotatate, bevacizumab, interferon, or everolimus were
highly efficacious. Also, the certainty of evidence for these
therapies was variable and was highest for somatostatin ana-
logues plus 177Lu-dotatate.
Second, the results suggest a range of monotherapies that
are superior to placebo, including everolimus, interferon, and
sunitinib in pNETs, and somatostatin analogues in pNETs and
GI-NETs. Conversely, the results did not demonstrate effi-
cacy superior to that of placebo for dactolisib in pNETs or for
interferon or everolimus in GI-NETs. The highest quality of evi-
dence was available for everolimus in pNETs, alone or in com-
bination with somatostatin analogues.
Third, the results indicate that NET therapies have a broad
range of risk for adverse events and effects on quality of life.
Because systemic treatment is commonly noncurative for
NETs, adverse events and quality of life are priorities. The re-
sults of this study may help to put the available safety data for
NET therapies into perspective. The findings may guide treat-
ment choice, initiate preventive measures, and result in in-
creased patient surveillance. In addition, they demonstrate the
need for more research in assessing adverse events and ef-
fects on quality of life for NET therapies.
Strengths and Limitations
This study has limitations. We conducted a comprehensive lit-
erature search with a sensitive search algorithm and an exten-
sive manual search of reference lists and conference proceed-
ings. We therefore consider it unlikely that we missed relevant
RCTs. However, we could not obtain additional unpublished
data and are aware that a substantial amount of information
is not available to the public. Thus, we cannot rule out publi-
cation bias.
When using the available information for therapeutic
decisions in treatment of NETs, we propose to consider the
following points regarding indirectness, transitivity, risk of
bias, inconsistency, incoherence, and imprecision. First,
meta-analyses are based on the assumption of directness, in
which populations, therapies, and outcomes of included
studies are aligned with population, therapies, and out-
comes targeted by the meta-analysis. Our meta-analysis tar-
geted all available therapies and included only studies
reporting disease control and/or progression-free survival.
Both factors ensured a certain degree of directness. Yet, indi-
rectness was introduced by RCTs including mixed popula-
tions of patients with pNETs and GI-NETs. We highlight all
comparisons that were affected by indirectness (eTables 4-7
in the Supplement) to allow incorporation of this fact into
clinical decision making.
Second, network meta-analyses are also based on the as-
sumption of transitivity, in which the included studies are simi-
lar enough to build a network. In this study, the well-defined
populations and outcomes resulted in a network with high over-
all transitivity. Yet, the different types of interferons3,17,18,30,38,39
and somatostatin analogues3,5,17,18,26,27,30,31,36,37,39 intro-
duced intransitivity for the loop of comparisons of inter-
feron, somatostatin analogues, and their combination, but
had no association with the certainty of evidence for the rest
of the network.
Table. Percentage of Patients With Adverse Events According to Treatment
Treatment
Grades, No./Total No. (%)a
Source, Reference No.3-4 All
Dactolisib 26/31 (83.9) 31/31 (100) 28
Everolimus + somatostatin analogue 67/98 (68.4) 81/98 (82.7) 27, 41
Capecitabine + streptozocin + cisplatin 25/40 (62.5) 37/40 (92.5) 42
Everolimus 309/521 (59.3) 291/316 (92.1) 1, 27, 29, 31, 32, 40
Capecitabine + streptozocin 18/43 (41.9) 41/43 (95.3) 42
177Lu-dotatate + somatostatin analogue 46/111 (41.4) 105/111 (94.6) 37
Hepatic arterial chemoembolization 3/12 (25.0) 11/12 (91.7) 49
Somatostatin analogue 72/344 (20.9) 226/324 (69.8) 26, 37, 39, 41, 45, 50
Placebo 92/480 (19.2) 278/363 (76.6) 26, 29, 32, 45, 46, 50
Hepatic arterial embolization 2/14 (14.3) 12/14 (85.7) 49
Interferon + somatostatin analogue 1/33 (3.0) 7/33 (21.2) 39
Telotristat 0 79/90 (87.8) 46
Abbreviation: 177Lu-dotatate,
radiolabeled lutetium Lu
177–dotatate.
a Adverse events were classified
according to the National Cancer
Institute Common Terminology
Criteria for Adverse Events: grade 1,
mild; grade 2, moderate; grade 3,
severe or medically significant; and
grade 4, life-threatening.
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Third, some RCTs had a high risk of bias due to absent
blinding, including the RCTs evaluating the 3 most effica-
cious therapies in GI-NETs: somatostatin analogues plus
bevacizumab,3,18 plus 177Lu-dotatate,37 or plus interferon.17 Ab-
sent blinding has been shown to be associated with an aver-
age exaggeration of estimated therapeutic effects of approxi-
mately 9%.52 However, the therapeutic effect for the 3
aforementioned therapies compared with placebo substan-
tially exceeds 9% and they most likely represent the superior
therapies in GI-NETs, although the extent of superiority needs
to be interpreted with caution.
Fourth, consistency describes the agreement between es-
timates of different studies for a specific comparison, while co-
herence describes agreement between direct and indirect es-
timates for a specific comparison. Owing to the relatively low
number of RCTs, the assessment of incoherence and incon-
sistency was limited. We identified 6 comparisons in which in-
direct and direct estimates differed considerably, without being
statistically significant, and 2 cases of inconsistency. Two RCTs
compared somatostatin analogues with placebo,26,36 and 3
RCTs compared somatostatin analogues with somatostatin ana-
logues plus interferon.17,30,39 Likely owing to different types
of somatostatin analogues and interferons, the RCTs found dif-
ferent effects regarding disease control and progression-free
survival.
Fifth, the low number of RCTs compared with the num-
ber of interventions induced imprecision to several compari-
sons, manifesting as wide 95% CIs that include or are close to
a null effect. A statistically significant effect does not auto-
matically represent a clinically relevant effect, and the con-
sequence of imprecision is that wide 95% CIs might include
significant but clinically irrelevant effects. As clinical rel-
evance often depends on an individual patient's situation, we
highlighted all comparisons that were affected by impreci-
sion (eTables 4-7 in the Supplement) to allow incorporation of
this fact into clinical decision making.
We used the GRADE system to assess the confidence in ef-
fect estimates for all comparisons, depending on indirect-
ness, transitivity, risk of bias, inconsistency, incoherence, and
imprecision. We incorporated the certainty of evidence in the
main results of our analysis (eTables 4-7 in the Supplement)
to highlight the most robust findings for further use in clini-
cal judgment.
Sixth, we used the end points disease control and progres-
sion-free survival for all network analyses, instead of overall
survival. Although overall survival is arguably the most rel-
evant clinical end point, it is used less frequently because it
requires a larger number of patients and longer follow-up. Use
of overall survival also prevents crossover trial designs and
might be confounded by the effect of salvage therapies used
after disease progression.53 In NETs, progression-free sur-
vival has been shown to be well correlated with overall
survival,54 and the RCTs included in the present study re-
vealed the same correlation. Using disease control and
progression-free survival instead of overall survival in this
study allowed including more therapies into the network
meta-analyses, which we believe represents the preferred
approach.
Implications
Our results have implications for clinicians, guideline com-
mittees, and researchers. First, clinical decisions should be
based on the best available evidence. The present results pro-
vide a comprehensive overview of the existing evidence on
NET therapies as well as the best possible comparison of thera-
pies that have not been directly compared in RCTs. Using this
approach, the certainty of evidence is incorporated into the re-
sults to assist in decision making. Safety and efficacy results
should both be incorporated into the treatment decision, while
in addition the safety results may aid in the decision to estab-
lish preventive measures and increase the surveillance for
known toxic effects.
Furthermore, the results support the adaption of clinical
guidelines. Although there is no requirement to incorporate
all evidence from RCTs into clinical guidelines, this system-
atic review presents an overview of the existing evidence from
which guideline makers can choose. For example, evidence
from RCTs on alosetron,55 dactolisib,28 capecitabine,42
temozolomide,19 and surgical ligation devices56 in NETs has
not been integrated into many guidelines, and combination
therapies could be better represented. Everolimus plus a so-
matostatin analogue showed high efficacy in pNETs and is
widely recommended only by the Carcinoid-Neuroendo-
crine Tumor Society Canada.57 It is recommended solely for
functionally active pNETs by the ENETS, but not by the
NANETS.58,59 Interferon plus a somatostatin analogue showed
high efficacy and low toxic effects in pNETs and is recom-
mended for pNETs with reservation by the ENETS, but not by
NANETS.58,59 Conversely, 177Lu-dotatate plus a somatostatin
analogue showed high efficacy in GI-NETs and is recom-
mended by the NANETS, but not by the ENETS.58,60 Bevaci-
zumab plus a somatostatin analogue showed high efficacy in
GI-NET, but is not recommended by either the NANETS or
ENETS.58,60
Similarly, NET guidelines by the European Society for Medi-
cal Oncology,61 National Comprehensive Cancer Network,62
Scottish Neuroendocrine Tumour Group,63 and UK and Ire-
land Neuroendocrine Tumour Society64 do not recommend
combinations of everolimus, interferon, bevacizumab, or 177Lu-
dotatate plus a somatostatin analogue. Yet, the Scottish Neu-
roendocrine Tumour Group guidelines mention possible
benefits of bevacizumab or everolimus plus a somatostatin
analogue in pNET.63
The present results may guide future research by highlight-
ing necessary head-to-head comparisons and facilitating their
trial design.65 Specifically, dactolisib and everolimus plus beva-
cizumab plus a somatostatin analogue have only been com-
pared with 1 other active therapy in pNET yet, while everoli-
mus, everolimus plus a somatostatin analogue, bevacizumab
plus a somatostatin analogue, 177Lu-dotatate plus a somatosta-
tin analogue, and streptozocin plus fluorouracil have only been
compared with 1 other active therapy in GI-NETs. Sunitinib and
everolimus have been compared only with placebo in pNETs and
GI-NETs respectively, and, to our knowledge, head-to-head com-
parisons with active therapies in RCTs have not yet been per-
formed. When designing such head-to-head comparisons, the
estimated associations from our network meta-analysis can help
Research Original Investigation Therapeutic Options for Neuroendocrine Tumors
486 JAMA Oncology April 2019 Volume 5, Number 4 (Reprinted) jamaoncology.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Universität Bern User  on 12/19/2019
to select the reference therapy and approximate the required
patient numbers. Particularly, because the present results iden-
tified 7 therapies in pNETs and 5 therapies in GI-NETs with
higher efficacy than placebo, comparisons with placebo as a ref-
erence are discouraged for the future. Because of their proven
efficacy and central role in current comparisons, somatostatin
analogues represent the logical reference compound for fur-
ther RCTs. Moreover, the quality assessment of currently avail-
able RCTs revealed that further studies should incorporate blind-
ing to avoid overestimation of effects and improve the overall
quality of evidence in the field.
Conclusions
Herein, we present a systematic review and network meta-
analysis of available RCTs evaluating the safety and efficacy
of therapies for NETs. This overview of what we believe to be
the most pertinent and current evidence demonstrates a range
of efficient therapies with different safety profiles that are avail-
able for patients with NETs and may facilitate informed clini-
cal decision making, drafting of guidelines, and planning of
future research.
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Invited Commentary
Evaluating Risks and Benefits of Evolving Systemic
Treatments of Neuroendocrine Tumors
Jonathan Raphael Strosberg, MD; Taymeyah Al-Toubah, MPH; Mauro Cives, MD
In recent years, the number of treatments for metastatic, well-
differentiated gastrointestinal and pancreatic neuroendo-
crine tumors (NETs) has expanded significantly.1 New medi-
cations for tumor control as well as symptom control include
somatostatin analogues,
everolimus, sunitinib, telotri-
stat, and lutetium Lu 177
(177Lu)-dotatate. These new therapies have been approved
based on randomized clinical trials—an effort that has re-
quired international cooperation given the relative scarcity of
metastatic NETs.
With the introduction of new therapies, the problem of
treatment sequencing has arisen. Most studies in the NET
field have compared new treatments with a placebo or with
a comparator of unknown efficacy (eg, high-dose octreotide
in the Neuroendocrine Tumors Therapy (NETTER-1) registra-
tion trial for 177Lu-dotatate).2 Hence, it is difficult to compare
various active therapies and contrast benefits and risks.
To try to compare evidence across trials, Kaderli et al3
embarked on a systematic review and network meta-
analysis of randomized clinical trials. Their goal was to com-
pare disease control, progression-free survival, overall sur-
vival, toxic effects, and quality of life across trials, assigning
a P score, which measures the extent of certainty that one
treatment is superior to another, averaged over all compet-
ing therapies.
In this analysis, the authors faced challenges that are more
pertinent to the NET field than to most other cancers. First and
foremost, NETs are clinically and biologically heterogeneous
tumors. Some trials have evaluated midgut NETs, others have
evaluated pancreatic NETs, and yet others have investigated
gastroenteropancreatic NETs as a whole, with no clear break-
down of outcomes in specific subtypes. As a result, it is al-
most impossible to compare outcomes among different trials.
Other complicating factors include use of different response
criteria (eg, Response Evaluation Criteria in Solid Tumors vs
World Health Organization) across different trials, heteroge-
neous radiographic analysis (local vs central review), as well
as diverse baseline eligibility criteria (eg, progressive disease
at baseline or not). Thus, we encounter situations in which me-
dian progression-free survival in the placebo arm of one trial
is 6 months (PROMID study4: octreotide vs placebo) vs 18
months in the placebo arm of another (CLARINET study5:
lanreotide vs placebo). Because transitivity is one of the main
assumptions of network meta-analyses, as explained by
Kaderli et al,3 one may wonder whether this concept pertains
to NET trials.
Another problem is that the quality of the trials has var-
ied significantly over time. Early trials of interferon were sub-
stantially underpowered and nonblinded. This limitation has
complicated interpretation of subsequent trials, such as South-
west Oncology Group S0518,6 in which interferon was a con-
trol arm. Was bevacizumab, which performed no better than
interferon, an active drug in high-risk NETs or not? The an-
swer depends on the extent to which interferon is considered
an effective treatment.
The question of combination vs sequential therapy can-
not be addressed easily in this meta-analysis. Outcomes of com-
bination treatment are often superior but fail to answer the
fundamental question of whether treatments should be ad-
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